April 6, 2020
Announcement no. 8
Rights issue fully subscribed
By company announcement no. 6 of March 16, 2020, BioPorto A/S (“BioPorto”) announced the initiation of a right issue (the “Offering”) with pre-emptive subscription rights for the Company’s existing shareholders allowing for subscription of up to 24,992,054 new shares with a nominal value of DKK 1 each (the “New Shares”).
The subscription period for the New Shares has expired, and BioPorto is pleased to announce that all of the New Shares have been subscribed for. The offering is thus fully subscribed for.
The allocation of subscription orders for remaining shares will be communicated to the individual investors in due course.
The Offering will be completed when payment of subscription amounts have taken place and the New Shares have been registered with the Danish Business Authority, expectedly on April 14, 2020. The expected timetable in BioPorto’s company announcement no. 6 of March 16, 2020 remains unchanged.
Yours sincerely
BioPorto A/S
For further information, please contact:
Peter Mørch Eriksen, CEO
Ole Larsen, CFO
Telephone +45 4529 0000, e-mail: investor@bioporto.com
About BioPorto
BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].
Attachment
